Colorado’s PDAB Declares Third Drug Unaffordable 

On June 14, the Colorado Prescription Drug Affordability Board (PDAB) voted that a prescription drug used to treat various forms of psoriasis, arthritis, spondylitis, and hidradenitis suppurativa, was unaffordable for residents of the state. This is the third drug to receive an “unaffordable” designation from the Board. Since the drug has now been deemed unaffordable, the Board may now consider establishing upper payment limit (UPL) for the medication. View the PDAB’s affordability report. 

For more information on PDABs, view Aimed Alliance’s PDAB Fact Sheet: Challenges and Alternatives.